GLYCOMACROPEPTIDE FORMULA WITH DOCOSAHEXAENOIC ACID AND LOW PHENYLALANINE
Information current as at: 1 July 2026
Submission Details
- Brand name:
-
- PKU GMPro® Delight
- Form and strength:
-
Please search for and view the meeting agenda from the relevant meeting for more information
- Submission sponsor:
- NUTRICIA AUSTRALIA PTY LIMITED
- Condition/indication:
(therapeutic use) -
- Phenylketonuria (PKU)
- Listing requested:
- Please see meeting agenda for more information
- Funding program:
- PBS General Schedule
- Request authority level:
- Please see meeting agenda for more information
- PBAC Submission type:
- Change to listing (Category 3)
- Comment:
- --
- Other PBAC consideration:
- --
Progress Details
-
Submission received for: - March 2026 PBAC meeting
-
Opportunity for consumer comment: - Open 19/11/2025 and close 21/01/2026 (see PBS Website)
-
PBAC meeting: - Held on 11/03/2026
-
5Lodgement of required documentation:
- 13/05/2026
-
Acceptance of complete documentation:
- Under consideration
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
PBAC Outcome
The PBAC recommended listing glycomacropeptide formula with long chain polyunsaturated fatty acids docosahexaenoic acid and low in phenylalanine (PKU GMPro Delight®) sachets containing oral powder 40 g for the dietary management of phenylketonuria (PKU) under the same circumstances as glycomacropeptide formula with long chain polyunsaturated fatty acids and docosahexaenoic acid and low in phenylalanine (PKU Sphere20®) sachets containing oral powder 35 g for the same indication. The PBAC considered that PKU GMPro Delight should be cost-minimised to the comparator accepted by the NPWP (i.e. PKU Sphere20) at an equivalent price per gram of protein equivalent.